The stock has a 36-month beta value of 1.71. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADCT is 59.83M, and at present, short sellers hold a 1.48% of that float. On May 06, 2024, the average trading volume of ADCT was 603.83K shares.
ADCT) stock’s latest price update
Adc Therapeutics SA (NYSE: ADCT) has experienced a decline in its stock price by -5.64 compared to its previous closing price of 4.90. However, the company has seen a gain of 2.74% in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-06 that ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.56 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.74 per share a year ago.
ADCT’s Market Performance
Adc Therapeutics SA (ADCT) has experienced a 2.74% rise in stock performance for the past week, with a -7.53% drop in the past month, and a 26.67% rise in the past quarter. The volatility ratio for the week is 8.17%, and the volatility levels for the past 30 days are at 8.25% for ADCT. The simple moving average for the last 20 days is -0.95% for ADCT’s stock, with a simple moving average of 100.51% for the last 200 days.
Analysts’ Opinion of ADCT
Many brokerage firms have already submitted their reports for ADCT stocks, with Guggenheim repeating the rating for ADCT by listing it as a “Buy.” The predicted price for ADCT in the upcoming period, according to Guggenheim is $11 based on the research report published on March 28, 2024 of the current year 2024.
BofA Securities gave a rating of “Underperform” to ADCT, setting the target price at $2 in the report published on April 24th of the previous year.
ADCT Trading at 0.48% from the 50-Day Moving Average
After a stumble in the market that brought ADCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.45% of loss for the given period.
Volatility was left at 8.25%, however, over the last 30 days, the volatility rate increased by 8.17%, as shares sank -8.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.27% lower at present.
During the last 5 trading sessions, ADCT rose by +3.72%, which changed the moving average for the period of 200-days by +211.17% in comparison to the 20-day moving average, which settled at $4.65. In addition, Adc Therapeutics SA saw 178.52% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ADCT
Current profitability levels for the company are sitting at:
- -2.43 for the present operating margin
- 0.95 for the gross margin
The net margin for Adc Therapeutics SA stands at -3.44. The total capital return value is set at -0.59. Equity return is now at value -705.53, with -54.16 for asset returns.
Based on Adc Therapeutics SA (ADCT), the company’s capital structure generated -3.35 points at debt to capital in total, while cash flow to debt ratio is standing at -1.04. The debt to equity ratio resting at -0.77. The interest coverage ratio of the stock is -3.24.
Currently, EBITDA for the company is -145.78 million with net debt to EBITDA at 1.06. When we switch over and look at the enterprise to sales, we see a ratio of 3.22. The receivables turnover for the company is 2.76for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.97.
Conclusion
To sum up, Adc Therapeutics SA (ADCT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
